Derma Sciences Inc (NASDAQ:DSCI)

CAPS Rating: 1 out of 5

Recs

1
Player Avatar zzlangerhans (99.73) Submitted: 1/11/2013 7:54:26 PM : Underperform Start Price: $11.66 DSCI Score: +9.23

I've never been a believer in Derma so I'll fling myself onto this rising knife. There's no consistent upward trend in quarterly revenues and the company seems to be dragging their heels on a phase III trial of DSC127. Could that be because the FDA wants an active comparator instead of placebo and the company knows they won't get stat sig in ulcer healing with that approach? Meanwhile, the dilution continues.

As I've said before, I don't grudge Derma 100M in enterprise value. Above that I start getting skeptical.

Featured Broker Partners


Advertisement